Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer.

ABSTRACT: The global burden of advanced stage cervical cancer remains significant, particular in resource poor countries where effective screening programs are absent. Unfortunately, a proportion of patients will be diagnosed with advanced stage disease, and may suffer from persistent or recurrent disease despite treatment with combination chemotherapy and radiation. Patients with recurrent disease have a poor salvage rate, with an expected 5-year survival of less than 10%. Recently, significant gains have been made in the antiangiogenic arena; nonetheless the need to develop effective alternate targeted strategies is implicit. As such, a review of molecular targeted therapy in the treatment of this disease is warranted. In an era of biologics, combined therapy with cytotoxic drugs and molecular tar

SUBMITTER: Eskander RN 

PROVIDER: S-EPMC4102744 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature